Person:
Johannessen, Cory M.

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Johannessen

First Name

Cory M.

Name

Johannessen, Cory M.

Filters

20141

Settings

Author's Publications: search.filters.isAuthorOfPublication.4bb5cfa3-775b-405f-9dbf-8616271d07a3

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
    (2014) Johannessen, Cory M.; Johnson, Laura A.; Piccioni, Federica; Townes, Aisha; Frederick, Dennie T.; Donahue, Melanie K.; Narayan, Rajiv; Flaherty, Keith; Wargo, Jennifer Ann; Root, David E.; Garraway, Levi
    BRAFV600E-mutant malignant melanomas depend on RAF/MEK/ERK (MAPK) signaling for tumor cell growth1. RAF and MEK inhibitors show remarkable clinical efficacy in BRAFV600E melanoma2, 3; however, resistance to these agents remains a formidable challenge2, 4. Global characterization of resistance mechanisms may inform the development of more effective therapeutic combinations. Here, we performed systematic gain-of-function resistance studies by expressing >15,500 genes individually in a BRAFV600E melanoma cell line treated with RAF, MEK, ERK, or combined RAF/MEK inhibitors. These studies revealed a cyclic AMP-dependent melanocytic signaling network not previously associated with drug resistance, including G-protein coupled receptors, adenyl cyclase, protein kinase A and cAMP response element binding protein (CREB). Preliminary analysis of biopsies from BRAFV600E melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF/MEK-inhibition but restored in relapsing tumors. Expression of transcription factors activated downstream of MAP kinase and cAMP pathways also conferred resistance, including c-FOS, NR4A1, NR4A2 and MITF. Combined treatment with MAP kinase pathway and histone deacetylase inhibitors suppressed MITF expression and cAMP-mediated resistance. Collectively, these data suggest that oncogenic dysregulation of a melanocyte lineage dependency can cause resistance to RAF/MEK/ERK inhibition, which may be overcome by combining signaling- and chromatin-directed therapeutics.